ERBB2 and breast carcinoma: In luminal B-like breast cancer patients (HER2-independent), the C/C-genotype was associated with a significantly shortened event-free survival of only 54.8 months, compared with 74 months for A/A-patients (p < 0.001; log-Rank-test; Figure 6B).